$4.41
+0.09 (+2.08%)
Open$4.39
Previous Close$4.32
Day High$4.53
Day Low$4.32
52W High$24.77
52W Low$14.44
Volume—
Avg Volume430.0K
Market Cap102.50M
P/E Ratio35.83
EPS$0.52
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+412.9% upside
Current
$4.41
$4.41
Target
$22.62
$22.62
$15.82
$22.62 avg
$24.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 11.82M | 10.52M | 11.40M |
| Net Income | 3.06M | 2.28M | 2.66M |
| Profit Margin | 25.9% | 21.7% | 23.3% |
| EBITDA | 4.32M | 3.67M | 4.36M |
| Free Cash Flow | 3.21M | 3.03M | 2.01M |
| Rev Growth | +9.7% | +22.7% | +8.4% |
| Debt/Equity | 0.16 | 0.13 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |